Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26917325 | 0.69 | NAPRT (0.61) | CES1MAPK1 | |
| Hydrochloric Acid SCHEMBL27227698 | 0.68 | NAPRT (0.59) | CES1MAPK1 | |
| SCHEMBL8856874 | 0.66 | CES1 (0.39) | CES1MAPK1HTTIDO1PLA2G2D | |
| SCHEMBL6281925 | 0.64 | CES1 (0.34) | CES1MAPK1HTTIDO1PLA2G2D | |
| SCHEMBL3037744 | 0.63 | MAPT (0.50) | CES1MAPK1HTTIDO1PLA2G2D | |
| SCHEMBL30371054 | 0.63 | MAPT (0.50) | CES1MAPK1HTTIDO1PLA2G2D | |
| SCHEMBL17265820 | 0.62 | KDM4E (0.42) | CES1MAPK1HTTIDO1PLA2G2D | |
| SCHEMBL31146203 | 0.62 | KDM4E (0.47) | CES1MAPK1HTT | |
| SCHEMBL9100531 | 0.62 | KDM4E (0.39) | MAPK1 | |
| SCHEMBL28239864 | 0.61 | IKBKB (0.66) | CES1IDO1PLA2G2DACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2326639-B1 | SUBSTITUTED PYRIDINES AND ITS USE AS GSK3 INHIBITORS | BAYER IP GMBH (DE) | 2015-08-19 | — | — | EP | disclosed |
| US-8664246-B2 | Substituted pyridines, and use thereof as GSK3 inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-03-04 | — | — | US | disclosed |
| US-20110190316-A1 | Substituted pyridines, and use thereof as Gsk3 inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-04 | — | — | US | disclosed |
| EP-2326639-A1 | SUBSTITUTED PYRIDINES, AND USE THEREOF AS GSK3 INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-06-01 | — | — | EP | disclosed |
| EP-2229392-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE AS GSK3BETA INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-09-22 | — | — | EP | disclosed |
| WO-2010012398-A1 | SUBSTITUTED PYRIDINES, AND USE THEREOF AS GSK3 INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-04 | — | — | WO | disclosed |
| US-20090258877-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2009-10-15 | — | — | US | disclosed |
| WO-2009074259-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258877-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE | THPO, IL5, TPMT | CES1 3340/4885MAPK1 2197/4885HTT 1488/4885 |
| US-20110190316-A1 | Substituted pyridines, and use thereof as Gsk3 inhibitors | GSK3B, GSK3A, GSKIP | CES1 2631/4885MAPK1 163/4885HTT 3768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.